Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Themes | Quick Take |
|---|---|---|---|---|---|---|---|
Buyside Digest is not affiliated with, and does not endorse, Driehaus Small Cap Growth Fund. This analysis is provided for institutional research purposes only and is not investment advice.
"Driehaus Small Cap Growth strategy sharply outperformed its benchmark in Q4 and full-year 2025, driven by proactive adjustments like ramping up biotech exposure and trimming software, amid an accelerating small-cap earnings recovery."
The Driehaus Small Cap Growth strategy generated robust performance in Q4 2025, returning 5.58% (net) to outperform its Russell 2000 Growth benchmark which rose 1.22%. For the full year 2025, the fund returned 16.82% (net) versus 13.01% for the benchmark, marking its tenth year of benchmark outperformance out of the last eleven. The manager highlights that small cap earnings have recovered from a 2023-2024 recession and are poised to outpace large cap growth through 2026. Structurally, the portfolio made significant sector shifts during the quarter, heavily expanding its healthcare footprint (specifically within biotech/pharma) while reducing exposure to enterprise software and consumer discretionary names. Despite noted risks in trade policy, geopolitical events, and power grid bottlenecks for data centers, the firm maintains a bullish stance on small caps going into 2026.
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.
Market Conviction
High-conviction positioning: Driehaus Small Cap Growth strategy sharply outperformed its benchmark in Q4 and full-year 2025, driven by proactive adjustments like ramping up biotech exposure and trimming softwa...
Growth Outlook
Market outlook remains high conviction: Driehaus Small Cap Growth strategy sharply outperformed its benchmark in Q4 and full-year 2025, driven by proactive adjustments like ramping up biotech exposure and trimming softwa...
Risk Appetite
Risk appetite posture is above average conviction: Driehaus Small Cap Growth strategy sharply outperformed its benchmark in Q4 and full-year 2025, driven by proactive adjustments like ramping up biotech exposure and trimming softwa...
Capital Deployment
Manager actively deployed capital into high-conviction opportunities. Driehaus Small Cap Growth strategy sharply outperformed its benchmark in Q4 and full-year 2025, driven by proactive adjustments like ramping up biotech exposure and trimming softwa...
Forward Guidance
Forward guidance signal: Driehaus Small Cap Growth strategy sharply outperformed its benchmark in Q4 and full-year 2025, driven by proactive adjustments like ramping up biotech exposure and trimming softwa...
Language Signal
Tone analysis indicates high conviction language: Driehaus Small Cap Growth strategy sharply outperformed its benchmark in Q4 and full-year 2025, driven by proactive adjustments like ramping up biotech exposure and trimming softwa...
Perceived Risk
Perceived risk level is evaluated as moderate conviction. Driehaus Small Cap Growth strategy sharply outperformed its benchmark in Q4 and full-year 2025, driven by proactive adjustments like ramping up biotech exposure and trimming softwa...
Opportunity Density
Opportunity density index indicates high conviction actionable entry points. Driehaus Small Cap Growth strategy sharply outperformed its benchmark in Q4 and full-year 2025, driven by proactive adjustments like ramping up biotech exposure and trimming softwa...
Time Horizon
Investment time horizon reflects a high conviction orientation. Driehaus Small Cap Growth strategy sharply outperformed its benchmark in Q4 and full-year 2025, driven by proactive adjustments like ramping up biotech exposure and trimming softwa...
